Literature DB >> 21228032

Deep sequencing reveals double mutations in cis of MPL exon 10 in myeloproliferative neoplasms.

Daniela Pietra1, Angela Brisci, Elisa Rumi, Sabrina Boggi, Chiara Elena, Alessandro Pietrelli, Roberta Bordoni, Maurizio Ferrari, Francesco Passamonti, Gianluca De Bellis, Laura Cremonesi, Mario Cazzola.   

Abstract

Somatic mutations of MPL exon 10, mainly involving a W515 substitution, have been described in JAK2 (V617F)-negative patients with essential thrombocythemia and primary myelofibrosis. We used direct sequencing and high-resolution melt analysis to identify mutations of MPL exon 10 in 570 patients with myeloproliferative neoplasms, and allele specific PCR and deep sequencing to further characterize a subset of mutated patients. Somatic mutations were detected in 33 of 221 patients (15%) with JAK2 (V617F)-negative essential thrombocythemia or primary myelofibrosis. Only one patient with essential thrombocythemia carried both JAK2 (V617F) and MPL (W515L). High-resolution melt analysis identified abnormal patterns in all the MPL mutated cases, while direct sequencing did not detect the mutant MPL in one fifth of them. In 3 cases carrying double MPL mutations, deep sequencing analysis showed identical load and location in cis of the paired lesions, indicating their simultaneous occurrence on the same chromosome.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21228032      PMCID: PMC3069239          DOI: 10.3324/haematol.2010.034793

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  23 in total

1.  Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders.

Authors:  Francesco Passamonti; Elisa Rumi; Daniela Pietra; Matteo G Della Porta; Emanuela Boveri; Cristiana Pascutto; Laura Vanelli; Luca Arcaini; Sara Burcheri; Luca Malcovati; Mario Lazzarino; Mario Cazzola
Journal:  Blood       Date:  2005-12-22       Impact factor: 22.113

Review 2.  Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT).

Authors:  Ruben A Mesa; Srdan Verstovsek; Francisco Cervantes; Giovanni Barosi; John T Reilly; Brigitte Dupriez; Ross Levine; Marie-Caroline Le Bousse-Kerdiles; Martha Wadleigh; Peter J Campbell; Richard T Silver; Alessandro M Vannucchi; H Joachim Deeg; Heinz Gisslinger; Deborah Thomas; Olatoyosi Odenike; Lawrence A Solberg; Jason Gotlib; Elizabeth Hexner; Stephen D Nimer; Hagop Kantarjian; Attilio Orazi; James W Vardiman; Juergen Thiele; Ayalew Tefferi
Journal:  Leuk Res       Date:  2007-01-08       Impact factor: 3.156

3.  Anaemia characterises patients with myelofibrosis harbouring Mpl mutation.

Authors:  Paola Guglielmelli; Alessandro Pancrazzi; Gaetano Bergamaschi; Vittorio Rosti; Laura Villani; Elisabetta Antonioli; Alberto Bosi; Giovanni Barosi; Alessandro M Vannucchi
Journal:  Br J Haematol       Date:  2007-05       Impact factor: 6.998

4.  Molecular mechanisms associated with leukemic transformation of MPL-mutant myeloproliferative neoplasms.

Authors:  Philip A Beer; Christina A Ortmann; Frank Stegelmann; Paola Guglielmelli; John T Reilly; Thomas S Larsen; Hans C Hasselbalch; Alessandro M Vannucchi; Peter Möller; Konstanze Döhner; Anthony R Green
Journal:  Haematologica       Date:  2010-09-07       Impact factor: 9.941

5.  MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients.

Authors:  Animesh D Pardanani; Ross L Levine; Terra Lasho; Yana Pikman; Ruben A Mesa; Martha Wadleigh; David P Steensma; Michelle A Elliott; Alexandra P Wolanskyj; William J Hogan; Rebecca F McClure; Mark R Litzow; D Gary Gilliland; Ayalew Tefferi
Journal:  Blood       Date:  2006-07-25       Impact factor: 22.113

6.  Phenotypic variations and new mutations in JAK2 V617F-negative polycythemia vera, erythrocytosis, and idiopathic myelofibrosis.

Authors:  Donna M Williams; Ann H Kim; Ophelia Rogers; Jerry L Spivak; Alison R Moliterno
Journal:  Exp Hematol       Date:  2007-10-17       Impact factor: 3.084

7.  Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin.

Authors:  Jianmin Ding; Hirokazu Komatsu; Atsushi Wakita; Miyuki Kato-Uranishi; Masato Ito; Atsushi Satoh; Kazuya Tsuboi; Masakazu Nitta; Hiroshi Miyazaki; Shinsuke Iida; Ryuzo Ueda
Journal:  Blood       Date:  2004-02-05       Impact factor: 22.113

8.  Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia.

Authors:  Luciana Teofili; Fiorina Giona; Maurizio Martini; Tonia Cenci; Francesco Guidi; Lorenza Torti; Giovanna Palumbo; Angela Amendola; Robin Foà; Luigi M Larocca
Journal:  J Clin Oncol       Date:  2007-03-20       Impact factor: 44.544

9.  MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.

Authors:  Yana Pikman; Benjamin H Lee; Thomas Mercher; Elizabeth McDowell; Benjamin L Ebert; Maricel Gozo; Adam Cuker; Gerlinde Wernig; Sandra Moore; Ilene Galinsky; Daniel J DeAngelo; Jennifer J Clark; Stephanie J Lee; Todd R Golub; Martha Wadleigh; D Gary Gilliland; Ross L Levine
Journal:  PLoS Med       Date:  2006-07       Impact factor: 11.069

10.  MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort.

Authors:  Philip A Beer; Peter J Campbell; Linda M Scott; Anthony J Bench; Wendy N Erber; David Bareford; Bridget S Wilkins; John T Reilly; Hans C Hasselbalch; Richard Bowman; Keith Wheatley; Georgina Buck; Claire N Harrison; Anthony R Green
Journal:  Blood       Date:  2008-05-01       Impact factor: 22.113

View more
  20 in total

1.  Flow-FISH evaluation of telomere length in Philadelphia-negative myeloproliferative neoplasms.

Authors:  Chiara Elena; Elisa Rumi; Monica Portolan; Matteo G Della Porta; Cristiana Pascutto; Francesco Passamonti
Journal:  Haematologica       Date:  2011-08       Impact factor: 9.941

2.  Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis.

Authors:  Elisa Rumi; Daniela Pietra; Cristiana Pascutto; Paola Guglielmelli; Alejandra Martínez-Trillos; Ilaria Casetti; Dolors Colomer; Lisa Pieri; Marta Pratcorona; Giada Rotunno; Emanuela Sant'Antonio; Marta Bellini; Chiara Cavalloni; Carmela Mannarelli; Chiara Milanesi; Emanuela Boveri; Virginia Ferretti; Cesare Astori; Vittorio Rosti; Francisco Cervantes; Giovanni Barosi; Alessandro M Vannucchi; Mario Cazzola
Journal:  Blood       Date:  2014-07-01       Impact factor: 22.113

3.  Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms.

Authors:  Luca Malcovati; Elli Papaemmanuil; David T Bowen; Jacqueline Boultwood; Matteo G Della Porta; Cristiana Pascutto; Erica Travaglino; Michael J Groves; Anna L Godfrey; Ilaria Ambaglio; Anna Gallì; Matteo C Da Vià; Simona Conte; Sudhir Tauro; Norene Keenan; Ann Hyslop; Jonathan Hinton; Laura J Mudie; James S Wainscoat; P Andrew Futreal; Michael R Stratton; Peter J Campbell; Eva Hellström-Lindberg; Mario Cazzola
Journal:  Blood       Date:  2011-10-12       Impact factor: 22.113

4.  Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms.

Authors:  Elisa Rumi; Daniela Pietra; Paola Guglielmelli; Roberta Bordoni; Ilaria Casetti; Chiara Milanesi; Emanuela Sant'Antonio; Virginia Ferretti; Alessandro Pancrazzi; Giada Rotunno; Marco Severgnini; Alessandro Pietrelli; Cesare Astori; Elena Fugazza; Cristiana Pascutto; Emanuela Boveri; Francesco Passamonti; Gianluca De Bellis; Alessandro Vannucchi; Mario Cazzola
Journal:  Blood       Date:  2013-04-10       Impact factor: 22.113

Review 5.  Genetic and epigenetic alterations of myeloproliferative disorders.

Authors:  Jelena D Milosevic; Robert Kralovics
Journal:  Int J Hematol       Date:  2012-12-12       Impact factor: 2.490

Review 6.  Thrombocytosis in children and adolescents-classification, diagnostic approach, and clinical management.

Authors:  Clemens Stockklausner; C M Duffert; H Cario; R Knöfler; W Streif; A E Kulozik
Journal:  Ann Hematol       Date:  2021-03-12       Impact factor: 3.673

7.  JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes.

Authors:  Elisa Rumi; Daniela Pietra; Virginia Ferretti; Thorsten Klampfl; Ashot S Harutyunyan; Jelena D Milosevic; Nicole C C Them; Tiina Berg; Chiara Elena; Ilaria C Casetti; Chiara Milanesi; Emanuela Sant'antonio; Marta Bellini; Elena Fugazza; Maria C Renna; Emanuela Boveri; Cesare Astori; Cristiana Pascutto; Robert Kralovics; Mario Cazzola
Journal:  Blood       Date:  2013-12-23       Impact factor: 22.113

Review 8.  Genetic basis of MPN: Beyond JAK2-V617F.

Authors:  Nicole C C Them; Robert Kralovics
Journal:  Curr Hematol Malig Rep       Date:  2013-12       Impact factor: 3.952

9.  Nonfamilial, MPL S505N-Mutated Essential Thrombocythaemia.

Authors:  Ruth Morrell; Stephen E Langabeer; Liam Smyth; Meegahage Perera; Gerard Crotty
Journal:  Case Rep Hematol       Date:  2013-07-18

10.  A multiplex snapback primer system for the enrichment and detection of JAK2 V617F and MPL W515L/K mutations in Philadelphia-negative myeloproliferative neoplasms.

Authors:  Zhiyuan Wu; Yunqing Zhang; Xinju Zhang; Xiao Xu; Zhihua Kang; Shibao Li; Chen Zhang; Bing Su; Ming Guan
Journal:  Biomed Res Int       Date:  2014-03-05       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.